A Sneak Peek into Oncotarget

Oncotarget is an open access journal providing international peer-reviewed details covering research on oncology details every week. Published by the Impact Journal, the journal was launched in 2010 with Andrei V. Gudkov and Blagosklonny Mikhail as the chief editors. As of 2016/2017, Oncotarget has attained a journal impact of 5.168 with a total number of 6625 articles.Its main focus is on the pathological causes of all types of cancer diseases, prospective therapy target as well as the treatment protocols followed by cancer patients’ improvement. The journal also has a great motive on the impact of cancer management programs and the upcoming therapeutic clinics and perspective protocols of the patients like adherence, satisfaction, and quality life.

Through Oncotarget, patients who have cancer are informed of the new and current therapies revealing positive results through the acceptance of the patients.Oncotarget popularity and rapid growth have prompted the Impact Journal in publishing pathology on the paper. Compared to other Pathology papers, the Oncotarget Pathology Section will acquire several benefits including high impact factor and prompt publication. Also, with reviews and refutation, one can deliver a rejected paper from other popular journals via the submission system of Oncotarget, and in a matter of less than six days, a decision will be made.

Oncotarget Publishes the Gum Tissue Damage Causing E-cigarettes Study

Just like any other cigarette, Oncotarget study shows that the electronic cigarettes similarly cause damage to the teeth and gums. With the help of their research team, they were able to discover that vapors released by the electronic cigarettes produce inflammatory proteins that cause gum stress in cells. Such stress can damage the gums causing various oral ailments to the smokers. However, the extent of the damage will highly depend on the consistency of E-cigarette smokers.The study also provides a discovery of flavors used in the electronic cigarette that may also lead to the killing of mouth cells. FawadJaved, the co-author of the study, discovered that the cigarette contains nicotine, a harmful and gum disease causing substance. Dr. Mahmoud Rouabhia, the leader of the Oncotarget study, says that there are high chances for one to get cancer diseases after a prolonged use of the E-cigarette. However, the Oncotarget researchers are working on the same in order to establish it. The Journal has earned popularity in the world for having published the first study addressing the detrimental effects of electronic cigarettes on the mouth.

Learning More on Cancer From Eric Lefkofsky

Cancer is one of the deadliest and most difficult diseases to take control of, even in the modern era. As a result of this, research is always evolving but getting data is a very crucial aspect.

According to individuals like Eric Lefkofsky, more data on cancer is the one thing that is missing from the medical research system of the modern era because is how caner can be treated successfully. It is a known fact that there is tons and tons of patient data that is available but few if any sources that can combine that data with any genomic cancer information.

At the Fortune Brainstorm Health conference in San Diego, Lefkofsky stated that in addition to gathering molecular data, clinical data is also needed, like therapeutic and outcome response data. This means that not only is a patient’s DNA and RNA necessary but so are the kind of treatments that are used on patients and how they react to them. He specifically mentioned breast cancer and how certain treatments of patients can work for some patients but not the others, with variables such as if the patient is using other drugs.

Eric Lefkofsky is the CEO and co-founder of a group called Tempus, which is a technology company that is geared towards battling cancer using a special operating system. The goal of this was to enhance how electronic medial records (EMR) function by allowing it aggregate more patient data. Before founding the company, Lefkokfsy attended the University of Michigan and graduated with his Juris Doctor degree later on at the Michigan Law School. He has also served as an adjunct professor at the University of Chicago later on in life.

Upon the completion of college career, Lefkofsky founded the Lefkofsky Family Foundation in 2006, which was meant to create high-impact initiatives for sickness and serve the local communities. He has also been behind the creation of other projects such as being the chairman and co-founder of Groupon, a global marketplace that deals with commerce. He is also a founding partner for Lifebank which is a funding group specializing in technological advancement.

for details: www.tempus.com/about-us/